Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Gilead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of December 23,
Vir Biotech upgraded at Morgan Stanley on cancer drug data
Morgan Stanley upgraded Vir Biotechnology (NASDAQ:VIR) to Overweight from Equal Weight on Thursday after the cancer drug developer shared initial mid-stage trial data for two antitumor agents developed using Sanofi’s (SNY) PRO-XTEN masking platform.
Morgan Stanley (MS) Earnings Expected to Grow: Should You Buy?
Morgan Stanley (MS) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture,
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged
News Medical on MSN1d
HIV drug access remains a major challenge despite promising trial results
Promising new drugs to prevent and treat HIV have the potential to transform the response to the disease. But getting these ...
Lenacapavir: The 'Breakthrough Of The Year' Drug For HIV Care
A significant breakthrough in treating the Human Immunodeficiency Virus (HIV) came recently with the US Federal Drug ...
MIT Technology Review8d
Long-acting HIV prevention meds: 10 Breakthrough Technologies 2025
A new drug is hugely effective at protecting people from HIV infection and needs to be injected only twice a year.
Armed robbery in Revesby5d
WHO Unveils New Lenacapavir, HIV Testing Guidelines
WHO is convening a Guideline Development Group (GDG) for the development of new guidelines on the use of injectable ...
Managed Healthcare Executive4d
WHO to Develop Lenacapavir and HIV Testing Guidelines
A Guideline Development Group (GDG) meeting at the end of the month aims to establish new guidelines for lenacapavir, a twice ...
devdiscourse12d
Revolutionary HIV Drug: Lenacapavir Signals New Hope
Lenacapavir, approved by the US FDA, presents a groundbreaking advancement in the battle against HIV. Developed by Gilead ...
Iowa Public Radio1mon
This drug is the 'breakthrough of the year' -- and it could mean the end of the HIV epidemic
But 2024 has fueled increasing optimism among leading infectious disease experts after the results of two groundbreaking clinical trial results for a drug called lenacapavir showed it to be ...
punjabnewsexpress1d
Global diagnosed HIV prevalence to reach over 2.2 mn in 2033: Report
The diagnosed prevalent cases of human immunodeficiency virus (HIV) are projected to increase globally at an annual growth ...
Glassman: How Trump can meet his goal of ending AIDS
In Donald Trump’s 2019 State of the Union Address, he made “a commitment to eliminate the HIV epidemic in the United States ...
Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. (NASDAQ:GILD) on Substack by Magnus Ofstad. In this article, we will ...